Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations

Richard Paulson, CEO of Karyopharm Therapeutics, sold 11,694 shares of common stock to cover withholding tax liabilities from vesting restricted stock units.

Summary

• Richard Paulson, the President and CEO of Karyopharm Therapeutics Inc., sold 11,694 shares of common stock on March 4, 2025.
• The sale was executed at a price of $6.29 per share.
• The transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021.
• The purpose of the sale was to cover the withholding tax liability incurred upon the vesting of restricted stock units.
• Following the transaction, Paulson directly owns 82,984 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax purposes) and doesn't indicate any significant positive or negative sentiment.

Industry Context

Sales of shares to cover tax obligations are a routine part of executive compensation, particularly when dealing with equity-based compensation.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Karyopharm Therapeutics, Richard Paulson, stock sale, Form 4, CEO, tax liability, restricted stock units, automatic sale plan